Skip to main content
Download PDF
Download ePub

Correlation between remnant cholesterol and hyperuricemia in American adults

Lipids in Health and Disease volume 23, Article number: 176 (2024) Cite this article

Abstract

Background

Remnant cholesterol (RC) is an important marker for assessing the risk of metabolic syndrome. However, the correlation between RC and hyperuricemia (HUA) remains unclear. This study aimed to explore the correlation between RC and HUA in American adults.

Methods

A total of 9089 participants from the 2013–2020 National Health and Nutrition Examination Survey were investigated. The correlation between RC and the odds of HUA was evaluated using multivariate logistic regression analysis. The nonlinear correlation was described using fitted smoothed curves. The correlation in subgroups was analyzed based on race, gender, alcohol consumption, age, body mass index, waist circumference, diabetes and moderate physical activities.

Results

RC was correlated with uric acid (Spearman’s correlation coefficient = 0.208 in males and 0.215 in females; all P < 0.001). Multiple logistic regression analysis indicated a positive correlation between RC and the risk of HUA (odds ratio = 1.022 in males and 1.031 in females; all P < 0.001). Subgroup analysis revealed that the correlation was stronger in females, participants aged < 50 years, and those without diabetes. Furthermore, the generalized smooth curve fitting demonstrated a linear correlation between RC and HUA, without threshold or saturation effects.

Conclusion

Elevated RC significantly and positively correlated with HUA in American adults. This correlation was stronger among females, participants aged < 50 years, and those without diabetes.

Introduction

Hyperuricemia (HUA), characterized by the excessive production or inadequate excretion of uric acid, is a significant global health concern closely associated with gout and a variety of other medical conditions, impacting individuals of all genders and ages [1, 2]. HUA can serve as an independent risk factor for numerous systemic diseases, such as cardiovascular diseases, gout, chronic kidney disease and hypertension [3]. As of 2016, the prevalence of HUA has reached 21% worldwide [4], ranging from 14.6 to 20% in the United States [5]. Notably, there is a trend affecting younger individuals, with mean age of 38.6 years old. HUA can impose substantial health burdens on public health infrastructure [6]. Hence, it is imperative to develop a straightforward and expeditious detection technique for timely identifying individuals at heightened risk of HUA, enabling targeted interventions for disease prevention.

RC, an innovative atherogenic lipoprotein, refers to the cholesterol content present in triglyceride-rich lipoproteins, predominantly comprising chylomicron remnants, quite low-density lipoproteins, and intermediate-density lipoproteins. Typically, RC can be determined by subtracting the levels of high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) from Total cholesterol (TC), as calculated from a standard lipid profile [7]. Notably, mechanistic evidence indicated that elevated concentrations of RC are associated with low-grade inflammation, which are genetically affected by insulin resistance (IR) [8,9,10]. A study of a subject on the epidemiology demonstrated that as the level of RC increases, there will be a corresponding increase in the prevalence of T2DM, hypertension, and lipid disorders [11,12,13,14]. Furthermore, the correlation between RC and MetS is characterized by a positive feedback loop involving IR, chronic inflammation, hypertension and abnormal lipid metabolism. RC has the impact on these factors and its reciprocal correlation with the results in the accelerated progression of MetS [15,16,17,18].

Previous studies have explored the correlation between conventional lipid parameters such as TC or triglycerides (TG) and HUA [19,20,21,22], while the precise correlation between RC and HUA remains unclear. Consequently, this study aims to investigate the potential correlation between RC and HUA in American adults without receiving lipid-lowering treatment.

Methods

Subjects and research design

The data analyzed obtained from NHANES (2013–2020) were analyzed in this study, with a stratified, multi-stage probability and complex sample of the uninstituted population in the United States. The cross-sectional surveys were conducted by NCHS. Further information regarding NHANES methods can be accessed at www.cdc.gov/nchs/NHANEs/.

The study focuses exclusively on subjects aged 18 years old and above (n = 27,654), among which, 18,565 subjects were eliminated: (1) Those with missing data on uric acid, lipid profiles; (2) Those with a history of using lipid lowering drugs and uric acid-lowering drugs; (3) Those with severe diseases such as kidney disease and inflammatory disease. Consequently, a total of 9089 subjects aged 18–80 years old were involved in the final analysis (Fig. 1).

Fig. 1
figure 1

Flowchart of the sample selection from the 2013–2020 NHANES

Full size image

The implementation of NHANES was approved by NCHS Ethics Review Board, and all subjects have provided informed consent in written.

Anthropometric measurements

The following data including history of diabetes, alcohol intake, race (non-Hispanic white, non-Hispanic black, Hispanic (Mexican-American and other Hispanic), and other race/multiracial), physical activity, education and physical measurements, including weight, WC, height and blood pressure were collected at admission.

TC, glycosylated hemoglobin (HbA1c), LDL-C, uric acid (UA), fasting plasma glucose (FPG), TG, alanine aminotransferase (ALT), creatinine, glutamyl transpeptidase (GGT), aspartate aminotransferase (AST), albumin and HDL-C were collected in blood samples. Less than 3% of values were missed in total. Multiple imputation was performed for missing values. The detailed measuring method and acquisition process of each variable are available at www.cdc.gov/nchs/nhanes.

Definition of lipid‑related indicators

Serum or plasma TC, HDL-C, and LDL-C were measured in participants who fasted for more than 8.5 h while less than 24 h in the NHANES laboratory. Specifically, TC was measured with the enzymatic assay and HDL-C was measured with the immunoassay. LDL-C was calculated from the measured values of total cholesterol (TC), triglycerides, and HDL-C according to the Friedewald calculation: [LDL-C] = [TC]—[HDL-C]—[TG/5]. The concentration of triglycerides in serum or plasma was determined with the timed-endpoint method. The 2019 European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) guidelines for the management of dyslipidaemias recommend the use of TC minus HDL-C and LDL-C for RC calculation [23].

HUA was defined as a uric acid level exceeding 7 mg/dL in males and 6 mg/dL in females [24]. WC of central obesity was defined as ≥ 102 cm in males and ≥ 88 cm in females [25]. Lean weight was defined as BMI < 18.5 kg/m2, normal weight was defined as 18.5 ≤ BMI < 25 kg/m2, overweight defined as 25 ≤ BMI < 30 kg/m2, obesity defined as BMI ≥ 30 kg/m2. Waist-to-height ratio (WHtR) = WC (cm)/height (cm).

Statistical analysis

In this study, continuous data were presented as weighted mean ± SD, and categorical variables were represented as weighted proportions. The participants were stratified into four quartiles according to the levels of RC (Q1: <13.14; Q2: 13.14–20.10; Q3: 20.10-29.96; Q4: >29.96 in male group, Q1: <12.06; Q2: 12.06–17.94; Q3: 17.94–28.89; Q4: >28.89 in female group). To assess disparities among the quartiles, the categorical variables were determined with weighted χ2 test. The correlation between RC and the presence of HUA was assessed through Binary logistic regression models. In Model 1, no covariate was adjusted. In Model 2, the covariates that change at least 10% of the initial regression coefficient of the matching risk of RC-related HUA was regarded as confounding factors and adjusts them (race, age and WHtR were adjusted). In Model 3, it was considered to be a fully adjustment since all non-collinear variables were adjusted (WHtR, race, age, moderate activities, diabetes, education level, drinking, waist circumference, DBP, serum creatinine, TG, ALT, SBP, AST, GGT, FPG, albumin were adjusted). Subgroup analyses on key variables (gender, age, race, BMI, WC, diabetes, moderate activities as well as drinking) were also conducted to assess the effect stratified by prespecified risk factors and the potential interaction effect. The potential nonlinear correlation between RC and HUA probabilities as investigated through a smooth curve fitting. Statistical analysis was performed with EmpowerStats software and R, with the significance, P < 0.05.

Results

Baseline characteristics

A total of 9089 participants aged from 18 to 80 were included in this study, with the prevalence of HUA of 16.9%. As shown in Table 1, the prevalence of HUA reached 13.9% in females and 20.2% in males, respectively. Age, proportion individuals with diabetes, WC, BMI, WHtR, SBP, DBP, ALT, AST, GGT, TC, TG, uric acid LDL-C and RC levels were all higher in HUA patients than those in non-HUA patients with both genders (P < 0.001).

Table 1 Baseline characteristics of the study population stratified by HUA and gender
Full size table

Correlation between RC and metabolic parameters

The correlation between RC and metabolic parameters, as measured by Spearman’s correlation coefficient, can be found in Table 2. It was evident that RC was positively correlated with BMI, WC, WHtR, SBP, DBP, FPG, TC, TG, LDL-C, uric acid, and negatively correlated with HDL-C (Table 2).

Table 2 Spearmen’s correlation of RC levels with clinical and biochemical parameters
Full size table

Linear correlation between RC and HUA

Three weighted multivariate regression models were developed to examine the correlation between HUA and RC (Table 3). In the unadjusted model, RC was positively correlated with HUA probabilities (OR = 1.021 in male and 1.032 in female). The correlation still existed in Model 2(OR = 1.022 in male and 1.030 in female) and Model 3(OR = 1.022 in male and 1.031 in female). Moreover, compared with the lowest level of RC (Q1) in Model 3 (P < 0.001), HUA of the subjects in quartiles 3 and 4 increased. To further investigate the correlation between RC and HUA, a generalized additive model and smooth curve fittings were adopted (Fig. 2). Among all participants, RC had a linear correlation with HUA without threshold or saturation effects.

Table 3 Association between RC and hyperuricemia by logistic regression analysis
Full size table
Fig. 2
figure 2

The smooth curve fit for the association between RC and hyperuricemia

Full size image
Fig. 3
figure 3

Subgroups analysis for the association between RC and hyperuricemia by gender, age, BMI, WC, race, diabetes, moderate activities and drinking

Full size image

Subgroup analysis on correlation between RC and HUA

The consistency of the correlation between RC and the odds ratio of HUA across different demographic contexts was evaluated through a comprehensive subgroup analysis. Due to a small sample size with a BMI less than 18.5 kg/m2 and a prevalence rate of only 4.5% for hyperuricemia, it was not included in the subgroup analysis. As shown in Table 4, the positive correlation between RC and the odds ratio of HUA was not significantly affected by race, BMI, WC, moderate activities and drinking (P > 0.05 for all interactions). The correlation between RC and HUA odds ratio was stronger among female participants (OR = 1.031, P interaction < 0.001), among participants with age < 50 years old (OR = 1.029, P < 0.001), among non-diabetes (OR = 1.030, P interaction < 0.001).

Table 4 Association between RC and hyperuricemia stratified by gender, age, race, BMI, WC, diabetes, moderate activities and drinking
Full size table

The generalized additive model and fitted smoothing curve are consistent with multivariate logistic regression models for the different subgroup (Fig. 3).

Discussion

This study discovered a strong positive correlation between RC and the prevalence of HUA in American adults, even after adjusting for various confounding factors, and exhibited a linear correlation. Through subgroup analysis and interaction assessment, a stronger correlation was discovered in females, participants with age < 50 years old and those with non-diabetes. This is the first known study of the strong positive correlation between RC and the prevalence of HUA and the presence of age, gender and diabetes differences in American adults.

With the material living conditions have been improved and unhealthy lifestyles become more prevalent, the incidence rate of HUA continues to rise [5, 26,27,28]. Notably, the Atherosclerosis Risk in Communities Study including 9451 Americans regularly consumed high-fructose corn syrup, such as sugar-sweetened soda, reported a 34.8% development rate of HUA during a 6-year follow-up [29]. In this study, the prevalence of HUA was 16.9% among general American adults during 2013–2020. Furthermore, findings from the NHANES indicated a prevalence of HUA nearly 20% in general Americans during 2015–2017 [3]. It was evident that the prevalence of HUA in Americans keeps rising, mirroring trends observed in other countries globally.

Recent clinical and epidemiological studies have highlighted the role of dyslipidemia in the development of HUA, with NHANES III revealing a significant correlation between the levels of TG and TC and the levels of UA in serum of general adults [21]. Nakanishi et al. discovered that basal TG continued to serve as a significant predictor of new-onset HUA, even when patients with diabetes mellitus and those on long-term medications for specific chronic conditions were excluded [30]. A retrospective study of 3884 participants from medical examinations in Gansu, China, revealed a positive correlation between elevated TG and HUA [20]. RC is the cholesterol found in Triglyceride-Rich Lipoproteins (TRLs), encompassing very low-density lipoproteins, intermediate-density lipoproteins, and chylomicron remnants [31]. Cholesterol in TRLs has a more direct impact on the risk of cardiovascular disease [32]. A multi-center cohort study, with an 18-year follow-up period, demonstrated that elevated levels of RC pose a risk for the onset of atherosclerotic cardiovascular disease (ASCVD), beyond traditional cardiovascular risk factors such as LDL-C and ApoB [33]. Some scholars suggest that RC, rather than LDL-C, is linked to the development of cardiovascular disease [33]. Further studies have confirmed that RC not only predicts the risk for cardiovascular disease, but also the risk of metabolic disease [34,35,36]. HUA and cardiovascular diseases share common risk factors [37]. This cross-sectional study also confirmed that RC is positively correlated with the HUA.

This study showed that RC was positively correlated with DBP, BMI, WC, TG, FPG, SBP, TC, LDL-C and negatively correlated with HDL-C, which is consistent with previous studies. Additionally, it was found that the correlation between RC and TG was the strongest compared to that between RC and that with other components of MetS. This is consistent with previous studies, suggesting that TG is primarily transported by remnants and that the concentration of TG significantly increases with elevated levels of RC [13, 38]. These findings collectively suggest a strong correlation between RC levels and metabolic disorders.

Furthermore, whether the correlation between RC and HUA was influenced by various established risk factors was investigated through stratified analyses. This study revealed notable gender disparities in the correlation between RC and HUA, with a notably stronger correlation observed in females than that in males. Interestingly, a similar trend has been observed in the correlation between RC and the risks of chronic kidney disease, diabetes, and NAFLD [39,40,41]. Although the exact mechanism underlying these gender-specific differences are still uncertain, gender hormones such as estrogen may play a role. Existing literature supports the influential role of estrogen signaling via Estrogen Receptor alpha (ERα) in modulating lipid and glucose metabolism [42]. Therefore, the decreased in estrogen levels following menopause may result in the dysregulation of lipid metabolism, leading the increased the susceptibility of females to developing HUA.

In those at the age < 50 years old or those without diabetes, RC was associated with higher odds ratio for HUA than that in those older than 50 years or those with diabetes. Diabetic patients generally have lower levels of SUA than those without diabetes [43,44,45]. Decreased preglomerular resistance in diabetic patients helps to increase glomerular hyperfiltration, further promotes the excretion of UA, and leads to hypouricemia [46, 47]. Similarly, the islet function of diabetic patients was often damaged, which led to a decrease in insulin secretion in the body, downregulating the expression of renal urate transporters, reducing the reabsorption of UA, and reducing SUA levels [48]. Additionally, dietary irregularities and insufficient exercise in young individuals can lead to excessive fat accumulation, potentially influencing RC [49]. Therefore, HUA usually has a stronger correlation with RC in the younger or without diabetes population.

Several plausible mechanisms can be postulated to elucidate the correlation between RC and the development of HUA. First of all, the elevation of RC levels in body will lead to an induction of heightened production and utilization of free fatty acids, consequently accelerating the catabolism of adenosine triphosphate and resulting in an augmented production of serum uric acid [50]. Secondly, an elevated RC level has been found to be independently associated with a reduced estimated glomerular filtration rate and an increased risk of renal impairment, potentially leading to a diminished excretion of uric acid [41]. Lastly, RC can serve as a surrogate marker for IR [51], and IR is a factor closely related to the pathogenesis of HUA. IR has been shown that it can enhance renal urate reabsorption through the stimulation of URAT1 [52] and/or Nadependent anion co-transporter in brush border membranes of renal proximal tubule [52, 53]. This finding strengthened on previous studies showed a pathogenesis among hyperuricemia and dyslipidemia [54, 55].

Study strengths and limitations

Notably, the study benefits from a large sample size and the national representativeness of Americans. In addition, various indexes in the model were adjusted to enhance the reliability of the findings. Nonetheless, this study is subject to certain limitations. Firstly, the establishment of a causal correlation between RC and HUA was not feasible through cross-sectional studies. Secondly, the measurement of RC is not currently a standard component of clinical blood lipid testing through direct means, thus only RC levels can be calculated. Thirdly, American adults are restricted to the study, necessitating further prospective cohort research to validate and generalize the present results in a broader population.

Conclusion

In summary, elevated RC was independently associated with HUA in a sizable cohort of American adults. This correlation was particularly pronounced among females, those under 50 years old, and those without diabetes. The RC could serve as an effective biomarker for assessing the risk of HUA.

Data availability

The datasets generated and analysis during the current study are available in the NHANES, www.cdc.gov/nchs/NHANEs/.

References

  1. Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, Woolf A, March L. The global burden of gout: estimates from the global burden of Disease 2010 study. Ann Rheum Dis. 2014;73:1470–6.

    Article  PubMed  Google Scholar 

  2. George C, Leslie SW, Minter DA. Hyperuricemia. In StatPearls Treasure Island (FL) ineligible companies. Disclosure: Stephen Leslie declares no relevant financial relationships with ineligible companies. Disclosure: David Minter declares no relevant financial relationships with ineligible companies.; 2024.

  3. Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, Redon J, Stack AG, Tsioufis KP. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1–11.

    Article  CAS  PubMed  Google Scholar 

  4. Fang XY, Qi LW, Chen HF, Gao P, Zhang Q, Leng RX, Fan YG, Li BZ, Pan HF, Ye DQ. The Interaction between Dietary Fructose and Gut Microbiota in Hyperuricemia and gout. Front Nutr. 2022;9:890730.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and Hyperuricemia in the United States and Decadal trends: the National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71:991–9.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Xia Y, Wu Q, Wang H, Zhang S, Jiang Y, Gong T, Xu X, Chang Q, Niu K, Zhao Y. Global, regional and national burden of gout, 1990–2017: a systematic analysis of the global burden of Disease Study. Rheumatology (Oxford). 2020;59:1529–38.

    Article  CAS  PubMed  Google Scholar 

  7. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626–35.

    Article  CAS  PubMed  Google Scholar 

  8. Basu D, Bornfeldt KE. Hypertriglyceridemia and atherosclerosis: using Human Research to Guide mechanistic studies in animal models. Front Endocrinol (Lausanne). 2020;11:504.

    Article  PubMed  Google Scholar 

  9. Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128:1298–309.

    Article  CAS  PubMed  Google Scholar 

  10. Nordestgaard BG. Triglyceride-Rich lipoproteins and Atherosclerotic Cardiovascular Disease: New insights from Epidemiology, Genetics, and Biology. Circ Res. 2016;118:547–63.

    Article  CAS  PubMed  Google Scholar 

  11. Ye X, Kong W, Zafar MI, Chen LL. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovasc Diabetol. 2019;18:48.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Nordestgaard BG, Tybjaerg-Hansen A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. Curr Opin Lipidol. 2011;22:113–22.

    Article  CAS  PubMed  Google Scholar 

  13. Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014;141:358–67.

    Article  CAS  PubMed  Google Scholar 

  14. de Graaf J, van der Vleuten GM, ter Avest E, Dallinga-Thie GM, Stalenhoef AF. High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia. J Clin Endocrinol Metab. 2007;92:1269–75.

    Article  PubMed  Google Scholar 

  15. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201–29.

    Article  CAS  PubMed  Google Scholar 

  16. Arner P, Bernard S, Salehpour M, Possnert G, Liebl J, Steier P, Buchholz BA, Eriksson M, Arner E, Hauner H, et al. Dynamics of human adipose lipid turnover in health and metabolic disease. Nature. 2011;478:110–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Xiao C, Hsieh J, Adeli K, Lewis GF. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am J Physiol Endocrinol Metab. 2011;301:E429–446.

    Article  CAS  PubMed  Google Scholar 

  18. Jin J, Meng X, Wang D, Han B, Wu T, Xie J, Zhang Q, Xie D, Zhang Z. Association between ambient temperature and cardiovascular diseases related hospital admissions in Lanzhou, China. Heliyon. 2023;9:e12997.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Rafiullah M, Siddiqui K, Al-Rubeaan K. Association between serum uric acid levels and metabolic markers in patients with type 2 diabetes from a community with high diabetes prevalence. Int J Clin Pract. 2020;74:e13466.

    Article  CAS  PubMed  Google Scholar 

  20. Hou YL, Yang XL, Wang CX, Zhi LX, Yang MJ, You CG. Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. Lipids Health Dis. 2019;18:81.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Peng TC, Wang CC, Kao TW, Chan JY, Yang YH, Chang YW, Chen WL. Relationship between hyperuricemia and lipid profiles in US adults. Biomed Res Int 2015, 2015:127596.

  22. Zhang X, Meng Q, Feng J, Liao H, Shi R, Shi D, Renqian L, Langtai Z, Diao Y, Chen X. The prevalence of hyperuricemia and its correlates in Ganzi Tibetan Autonomous Prefecture, Sichuan Province, China. Lipids Health Dis. 2018;17:235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.

    Article  PubMed  Google Scholar 

  24. Liu R, Han C, Wu D, Xia X, Gu J, Guan H, Shan Z, Teng W. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. Biomed Res Int 2015, 2015:762820.

  25. Moura L, Pagotto V, Camargo Pereira C, de Oliveira C, Silveira EA. Does abdominal obesity increase All-Cause, Cardiovascular Disease, and Cancer Mortality risks in older adults? A 10-Year Follow-Up analysis. Nutrients 2022, 14.

  26. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15:123.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Kumar AUA, Browne LD, Li X, Adeeb F, Perez-Ruiz F, Fraser AD, Stack AG. Temporal trends in hyperuricaemia in the Irish health system from 2006–2014: a cohort study. PLoS ONE. 2018;13:e0198197.

    Article  Google Scholar 

  28. Wang H, Zhang H, Sun L, Guo W. Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases. Am J Transl Res. 2018;10:2749–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Bomback AS, Derebail VK, Shoham DA, Anderson CA, Steffen LM, Rosamond WD, Kshirsagar AV. Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. Kidney Int. 2010;77:609–16.

    Article  CAS  PubMed  Google Scholar 

  30. Nakanishi N, Yoshida H, Nakamura K, Suzuki K, Tatara K. Predictors for development of hyperuricemia: an 8-year longitudinal study in middle-aged Japanese men. Metabolism. 2001;50:621–6.

    Article  CAS  PubMed  Google Scholar 

  31. Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34:1826–33.

    Article  CAS  PubMed  Google Scholar 

  32. Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic Cardiovascular Disease Risk. Endocr Rev. 2019;40:537–57.

    Article  PubMed  Google Scholar 

  33. Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, Lima J, Puri R, Nomura S, Tsai M, et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021;42:4324–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Chen J, Su Y, Su X, Luo F. Remnant cholesterol has a non-linear association with non-alcoholic fatty liver disease. Diabetes Res Clin Pract. 2023;201:110733.

    Article  CAS  PubMed  Google Scholar 

  35. Huang H, Xie J, Zeng Y, Liu Z, Miao M, Xu L, Xu C. Remnant cholesterol independently predicts the development of nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2023;108:2907–15.

    Article  PubMed  Google Scholar 

  36. Szili-Torok T, Sokooti S, Oste MCJ, Gomes-Neto AW, Dullaart RPF, Bakker SJL, Tietge UJF. Remnant lipoprotein cholesterol is associated with incident new onset diabetes after transplantation (NODAT) in renal transplant recipients: results of the TransplantLines Biobank and cohort studies. Cardiovasc Diabetol. 2022;21:41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Pillinger MH, Bangalore S, Klein AB, Baumgartner S, Morlock R. Cardiovascular Disease and gout: real-world experience evaluating patient characteristics, Treatment Patterns, and Health Care utilization. J Manag Care Spec Pharm. 2017;23:677–83.

    PubMed  Google Scholar 

  38. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427–36.

    Article  CAS  PubMed  Google Scholar 

  39. Zou Y, Lan J, Zhong Y, Yang S, Zhang H, Xie G. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. Lipids Health Dis. 2021;20:139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Hu X, Liu Q, Guo X, Wang W, Yu B, Liang B, Zhou Y, Dong H, Lin J. The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus. Cardiovasc Diabetol. 2022;21:117.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Yan P, Xu Y, Miao Y, Bai X, Wu Y, Tang Q, Zhang Z, Yang J, Wan Q. Association of remnant cholesterol with chronic kidney disease in middle-aged and elderly Chinese: a population-based study. Acta Diabetol. 2021;58:1615–25.

    Article  CAS  PubMed  Google Scholar 

  42. Palmisano BT, Zhu L, Stafford JM. Role of Estrogens in the regulation of liver lipid metabolism. Adv Exp Med Biol. 2017;1043:227–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Okada M, Ueda K, Omae T, Takeshita M, Hirota Y. The relationship of serum uric acid to hypertension and ischemic heart disease in Hisayama population, Japan. J Chronic Dis. 1982;35:173–8.

    Article  CAS  PubMed  Google Scholar 

  44. Tuomilehto J, Zimmet P, Wolf E, Taylor R, Ram P, King H. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol. 1988;127:321–36.

    Article  CAS  PubMed  Google Scholar 

  45. Li H, Sun M, Huang C, Wang J, Huang Y. Association between Glycosylated Hemoglobin and Serum Uric Acid: A US NHANES 2011–2020. Int J Endocrinol 2024, 2024:5341646.

  46. Cortinovis M, Perico N, Ruggenenti P, Remuzzi A, Remuzzi G. Glomerular hyperfiltration. Nat Rev Nephrol. 2022;18:435–51.

    Article  PubMed  Google Scholar 

  47. Golik A, Weissgarten J, Cotariu D, Cohen N, Zaidenstein R, Ramot Y, Averbukh Z, Modai D. Renal uric acid handling in non-insulin-dependent diabetic patients with elevated glomerular filtration rates. Clin Sci (Lond). 1993;85:713–6.

    Article  CAS  PubMed  Google Scholar 

  48. Toyoki D, Shibata S, Kuribayashi-Okuma E, Xu N, Ishizawa K, Hosoyamada M, Uchida S. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. Am J Physiol Ren Physiol. 2017;313:F826–34.

    Article  CAS  Google Scholar 

  49. Correa-Rodriguez M, Gonzalez-Jimenez E, Fernandez-Aparicio A, Luis Gomez-Urquiza J, Schmidt-RioValle J, Rueda-Medina B. Dietary Energy Density is Associated with Body Mass Index and Fat Mass in Early Adulthood. Clin Nurs Res. 2021;30:591–8.

    Article  PubMed  Google Scholar 

  50. Balasubramanian T. Uric acid or 1-methyl uric acid in the urinary bladder increases serum glucose, insulin, true triglyceride, and total cholesterol levels in Wistar rats. ScientificWorldJournal. 2003;3:930–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Fukushima M, Taniguchi A, Nakai Y, Sakai M, Doi K, Nin K, Oguma T, Nagasaka S, Tokuyama K, Seino Y. Remnant-like particle cholesterol and insulin resistance in nonobese nonhypertensive Japanese glucose-tolerant relatives of type 2 diabetic patients. Diabetes Care. 2001;24:1691–4.

    Article  CAS  PubMed  Google Scholar 

  52. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447–52.

    Article  CAS  PubMed  Google Scholar 

  53. Perez-Ruiz F, Aniel-Quiroga MA, Herrero-Beites AM, Chinchilla SP, Erauskin GG, Merriman T. Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. Rheumatol Int. 2015;35:1519–24.

    Article  CAS  PubMed  Google Scholar 

  54. Lu W, Song K, Wang Y, Zhang Q, Li W, Jiao H, Wang G, Huang G. Relationship between serum uric acid and metabolic syndrome: an analysis by structural equation modeling. J Clin Lipidol. 2012;6:159–67.

    Article  PubMed  Google Scholar 

  55. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, Burnier M. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004;4:9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank the NHANES database for providing the data source for this study.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Hematology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, P. R. China

    Xiaohai Zhou

  2. Department of Endocrinology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, P. R. China

    Xiaolu Weng & Jing Xu

  3. Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, P. R. China

    Wenxing Wang

Authors
  1. Xiaohai Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaolu Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenxing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

WXW designed the study; JX collected biochemical data; XHZ and XLW drafted the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Wenxing Wang.

Ethics declarations

Ethics approval and consent to participate

The National Center for Health Statistics Ethics Review Board has approved the implementation of NHANES.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, X., Weng, X., Xu, J. et al. Correlation between remnant cholesterol and hyperuricemia in American adults. Lipids Health Dis 23, 176 (2024). https://doi.org/10.1186/s12944-024-02167-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12944-024-02167-0

Keywords

Lipids in Health and Disease

ISSN: 1476-511X